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ABSTRACT 
In an era where ultra-high antibody concentrations, high viscosities, low volumes, auto-injectors, 
and long storage requirements are already complex problems with the current unconjugated 
monoclonal antibodies on the market the formulation demands for antibody-drug conjugates 
(ADCs) are significant.  Antibodies have historically been administered at relatively low 
concentrations through intravenous (IV) infusion due to their large size and the inability to 
formulate for oral delivery.  Due to the high demands associated with IV infusion and the 
development of novel antibody targets and unique antibody conjugates more accessible routes of 
administration such as intramuscular (IM), and subcutaneous (SC) are being explored. This 
review will summarize various site-specific and non-site-specific antibody conjugation 
techniques in the context of antibody-drug conjugates (ADCs) and the demands of formulation 
for high concentration clinical implementation.   
Statement of Significance: Antibody-drug conjugates utilize a variety of site-specific and non-
site-specific conjugation techniques. This review will detail some of the issues that may arise as 
heterogeneous antibody conjugate mixtures are formulated at high concentrations for use in 
clinical applications. 
KEYWORDS: formulation; antibody; conjugation; antibody-drug conjugates; ADC; high 
concentration; site-specific; heterogeneity 
INTRODUCTION 
Antibodies are produced in a variety of forms, from full length naked antibodies to 
conjugated antibodies or antibody fragments.  Antibodies themselves are capable of activating or 
inhibiting a target in-vivo through either competitive binding, sequestration, or providing a 
means of foreign body tagging inherit in the antibody Fc backbone structure.  The first 
unmodified antibody was a murine anti-CD3 antibody (Muromonab) developed as a reversal 
agent to mitigate kidney transplant rejection and was approved in the US in 1986.  To date there 
have been >60 FDA approved unmodified monoclonal antibodies.  Pharmaceutical antibodies 
consistently are ranked amongst the highest grossing pharmaceuticals with the top five having 
combined annual sales that exceed $40 billion/yr.(1)  Antibodies have come a long way since 
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1986 with the advent of chimeric and humanization processing that help minimize host immune 
activation against the administered antibodies themselves.  With >550 monoclonal antibodies 
currently in the clinical pipeline, in both cancer and non-cancer indications, the number of 
monoclonal antibodies with unique clinical targets will continue to rise.(2-4)  There is no 
question whether or not these first-generation antibodies will continue to be developed; however, 
next-generation antibody-drug conjugates (ADCs) have already begun to gain a clinical footing 
with four currently approved ADC formulations with cancer specific indications.(4,5)  This 
review will detail some of the issues that may arise in the field as heterogeneous antibody 
conjugate mixtures are formulated at high concentrations for clinical use.(6) 
ANTIBODY FORMULATION 
After a clinical target has been determined and an antibody has been selected it is 
necessary to formulate the antibody therapeutic prior to clinical use.  Antibody formulation is a 
complex optimization process utilizing unique pharmaceutical additives to address the varying 
demands of storage, freeze-thaw, and route of administration necessary for the clinical 
application.  There has been an ever-growing trend to increase the concentration of antibody-
based therapeutics for clinical applications making the formulation process more difficult.  This 
is largely driven by the desire to decrease the volume of injection while still providing for the 
same dose of drug to be administered.  The primary reason for this industry push is to enhance 
clinical outcomes and to allow for more flexible routes of administration.  
Most antibody therapeutics are given systemically through an IV requiring a healthcare 
professional to first attain venous access and then set up the infusion.  IV is an excellent route of 
drug administration for large volume drugs but the complications and difficulties that arise with 
venipuncture make IV less accessible than comparable intramuscular (IM) and subcutaneous 
(SC) injection modalities.  It is important to note that there is a limit to the volume (< 1.5 mL) 
that can be injected SC which is why antibody formulations are being pushed toward the 100’s of 
mg/mL concentrations to allow for smaller volumes while still being able to attain a 
therapeutically relevant delivery of the pharmaceutical agent.(6,7)  IM and SC administration 
also provides for different release kinetics, bioavailability, and extended half-life in some 
instances that can allow the periods between drug administrations to potentially be extended.(8)  
With the development of antibodies for more chronic diseases having a subcutaneous injection 
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route would allow for self-administration of a drug, similar to insulin, which would greatly 
increase accessibility.  For these reasons it is not surprising that antibody formulation has been 
pushing the boundaries of concentration.  To add to the complexity it is not simply sufficient to 
formulate an antibody at a very high stable concentration as the resulting formulation must also 
fall within physical parameter boundaries of viscosity.(9,10)  This is particularly important for 
auto-injectors but also plays a role in syringe based injection with various syringe geometries and 
loading assemblies helping to improve tolerance of high viscosity formulations.  At ultra-high 
viscosities it is nearly impossible to force the high antibody concentration formulation through a 
small bore needle making administration, regardless of stability, unreasonable.(11,12)  
Antibody formulation is best addressed early and often through the entirety of the 
antibody development lifecycle with the final antibody formulation for clinical use being 
finalized as early as possible in the development process.  It is a mistake to not consider the 
demands of formulation upon selection of a lead compound early in development as not every 
antibody can be formulated in any way to achieve a specific outcome.  Each unique delivery 
method (IV, IM, SC, auto-injector), unique molecular entity (antibody, protein, nanoparticle, 
small molecule), and unique target (cancer, non-cancer) require different formulation conditions 
to ensure that maximum stability and shelf-life can be attained.(13-15)  The process of 
formulating an antibody therapeutic is complex requiring first an understanding of how the 
protein handles exposure to stressors such as: freeze/thaw, agitation, thermal stability, and 
pH/buffer response followed by the addition of excipients to mitigate undesirable protein 
instabilities.(16,17)  An excipient is any additive that is included in a formulation that is used to 
stabilize the formation that is not considered an active ingredient.  Example excipients include: 
fillers, extenders, diluents, solvents, preservatives, absorption enhancers, and sustained-release 
matrices.  There is a relatively short list of buffers and excipients that are currently FDA 
approved for formulation of antibodies which greatly limits the space for high concentration 
optimization.  Pharmaceutical companies are hesitant to introduce new excipients due to the high 
regulatory burden associated with getting a new excipient approved in the context of the already 
high regulatory burden in getting the antibody, and its subsequent clinical formulation, approved 
as well.  
Most pharmaceutical antibodies are monoclonal antibodies meaning that each antibody 
molecule is identical to all other antibody molecules in solution.  Despite this fact, formulating 
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high concentrations of antibodies that retain a clinically significant self-life is not a trivial task.  
Antibodies are large proteins made up of >1,200 amino acids and have a propensity to aggregate 
at high concentrations making formulation optimization difficult.(18,19)  With the onset of 
polyclonal antibodies, antibody-drug conjugates (ADCs), and mixtures of monoclonal antibody 
therapeutics the already difficult task of antibody formulation becomes much more complicated 
as formulation difficulty is often correlated to sample complexity (Figure 1).   
To address the high demands for stability and concentration and the limited number of 
approved stabilizing compounds a large amount of effort has been placed on the sequence of 
optimization steps used to produce the most stable final antibody formulation.  An example of 
this is to first test a series of buffers and buffer concentrations and select for the most stable 
buffer composition. Following buffer selection excipients are then added sequentially, 
optimizing at each step, to selectively mitigate instabilities observed as concentration is 
increased modulating pH, ionic strength, surfactants, cryoprotectants, and other stabilizing agents 
working toward a final clinical formulation.  There are a number of techniques utilized to 
determine the optimal formulation for each unique monoclonal antibody or ADC.  Common 
characterization techniques that assess the antibody stability and activity following exposure to 
diverse stressed conditions include: size exclusion chromatography (SEC) to detect aggregate 
formation, ion-exchange chromatography (IEC) or isoelectric focusing to detect charge variants 
generated by chemical instability, capillary electrophoresis sodium dodecyl sulfate (CE-SDS) for 
detection of fragmentation, mass spectrometry, and potency assays for biological activity.(20,21)  
Typical methodologies for assessing the antibody stability in its native formulation state include: 
molecular modeling to assess surface characteristics, dynamic light scattering (DLS) to assess 
self-association propensity and pH effects, isothermal chemical denaturation (ICD) to assess 
optimal buffer conditions, differential scanning calorimetry (DSC) to assess thermal stability, 
and particulate formation characterization.(22)   There are a number of proprietary formulation 
platforms that automate some of the processing but it is important to note that the ultimate 
formulation determination does depend on the route of optimization as different routes 
infrequently result in the same final optimized formulation.  
ANTIBODY CONJUGATION 
While the capabilities of unconjugated, first-generation antibodies, are impressive there is 
a growing trend toward endowing the native antibody with unnatural capabilities (immuno-
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conjugates) to enhance therapeutic efficacy.    This comes in the most common form as a 
treatment of cancer utilizing antibody-drug-conjugates (ADCs).  ADC formulations possess 
conjugated cytotoxic drugs that have enhanced localized effects through targeted delivery 
utilizing the antibody to provide specificity and the cytotoxic payload as an active agent.  There 
are several different methods (both site-specific and non-site-specific) to conjugate functional 
ligands to antibodies.  Conjugation options for antibody modification can be split into three 
primary categories: naturally occurring sites of modification that exist in the native antibody 
structure (Natural), non-naturally occurring sites that can be added to the antibody backbone 
through genetic manipulation (Non-Natural), and unique (Specialty) antibody modification 
modalities that do not fall neatly in either the Natural or Non-Natural modification categories 
(Figure 2).  The categories and highlighted techniques detailed below are not intended to be an 
exhaustive list rather representative examples of commonly utilized conjugation 
strategies.(3,5,23,24)  Selection of an optimal conjugation technique is dependent on a number of 
factors including: the payload to be attached, the intended target, the amount of conjugations 
needed to attain therapeutic efficacy, the ability to conjugate without negatively affecting 
antibody specificity, and the tolerance for heterogeneity across the conjugated antibody 
population.(25)  An important measure of heterogeneity is the drug-antibody-ratio (DAR).  
Minimizing the variability in DAR is important as higher heterogeneity can result in varied 
pharmacokinetics, reduced half-life, increased plasma clearance, increased toxicity, and will 
increase the difficulty to attain a stable clinical formulation.  
Natural 
Antibodies are relatively large ~150 kDa glycoproteins that have many naturally 
occurring sites for conjugation.  There are chemistries for conjugating to many of the 20 
canonical amino acids.(26,27)  Despite the numerous available chemistries, the most common 
site for conjugation to proteins in general is through the ε-amine lysine side chain (1).  Due to the 
high abundance of lysine residues (>80 in the native antibody backbone), its positive charge, its 
relatively long extension into solution, and its readily accessible aqueous conjugation techniques 
it remains the most utilized technique despite not being site-specific.(28,29)  While the high 
lysine abundance is useful for attaining high levels of conjugation to the antibody surface there is 
limited-to-no control over the number of conjugations per antibody (DAR), or their relative 
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locations on the antibody surface.(30,31)  For this reason it is not uncommon to have a highly 
heterogeneous conjugated antibody population with some of the conjugations occurring to the 
Fab, the Fc and even to the antigen binding complementarity-determining region (CDR) 
resulting in partial inactivation of the conjugated antibody population.  A modification to this 
amine conjugation technique is carried out under stringent conditions allowing for selective 
conjugation to the N-terminus of the antibody heavy and light chains taking advantage of the 
differing pKa value of the lysine ε-amine vs the N-terminus α-amine (2).(32,33)  Due to the 
proximity of the N-terminus to the antigen binding region there are some issues associated with 
steric interference to antigen binding following conjugation. 
Another common naturally occurring amino acid that can be utilized for conjugation is 
the cysteine side chain.  It is uncommon for the cysteine thiol group to be in its free-reduced 
form in nature as they are often found to be conjugated to another cysteine residue through a 
disulfide bond and this is no different in antibodies.  Most antibodies have four inter-chain 
disulfide bonds that hold together the antibody heavy chains in the hinge region and the heavy 
and light chains in the Fab region.(34,35) Due to the significantly reduced number of reactive 
sites, compared to lysine conjugation, there is a corresponding greatly reduced heterogeneity 
observed in the resulting antibody conjugate.  The disulfide bonds in the hinge region can be 
selectively reduced providing for a site-specific location to conjugate a thiol reactive linker, such 
as maleimide, which results in the formation of a thioether bond (3).(36,37)  These disulfide 
bonds can also be utilized as targets for disulfide bond exchange allowing for an alternate site-
specific conjugation methodology utilizing the canonical cysteine residues.(38,39) 
Antibodies undergo post translational modifications, including glycosylation, which 
provide for an additional unique naturally occurring site for conjugation (4).  A reactive aldehyde 
group can be created at the carbohydrate locations through an oxidization reaction via the 
addition of sodium periodate allowing for further reaction with hydrazide functionalized 
linkers.(40,41)  Due to the side reactions associated with periodate exposure, and the varied 
nature and composition of post translational protein modifications this technique requires 
significant optimization from antibody-to-antibody.(42-44) It is important to note that neither the 
carbohydrate, nor the N-terminal heavy and light chain modification strategies have been utilized 
in any late-stage ADC formulations.  
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Relatively recently an alternate strategy for conjugation was described utilizing a highly 
conserved binding site present in nearly all antibody isotypes and across species between the 
heavy and light chains within the antibody variable region known as the Nucleotide Binding Site 
(NBS, 5).(45,46)  This conjugation strategy provides for two sites of conjugation, lending to the 
native antibody symmetry, and is achieved through UV activation of an NBS targeting small 
molecule such as an indole.(45,47)  While this conjugation strategy is appealing it has yet to be 
validated in animal studies due to its recent development and has therefore not been utilized 
clinically. 
Non-Natural 
There are two primary non-natural antibody modification techniques that require 
utilization of genetic engineering to either insert a non-natural amino acid (6) or place an 
engineered cysteine residue (7) in the antibody backbone for subsequent conjugation.  By adding 
a non-native cysteine the inter-chain disulfide bonds that maintain the antibody tertiary structure 
can remain intact while still allowing for utilization of the highly developed thiol-specific 
chemistries and linkers.(48)  These conjugation strategies result in the most homogenous 
modified antibody population but require the most intensive upfront development.(49,50)  The 
addition of non-canonical amino acids has also been explored to take advantage of alternate, 
orthogonal, chemical ligation strategies to improve conjugation homogeneity.(51-54)  As a non-
naturally occurring antibody modification each antibody would need to be specifically expressed 
with the backbone modification making this technique less desirable as off-the-shelf antibodies 
cannot be readily modified.  The backbone modification sites must be carefully tested to ensure 
that the resulting conjugated antibody maintains its other desirable engineered features such as 
extended serum half-life and immune activation capabilities, whenever relevant for each unique 
application.(55,56)  
Specialty 
Other antibody modification strategies include protein-protein interactions (8), 
engineered tags (9), and antibodies that possess catalytic activity (10).  The most common 
example of a protein-protein interaction (8) is the use of an Fc-specific protein to bind an 
antibody such as the ZZ-domain which was engineered from the IgG binding domain of 
Staphylococcal protein A (SPA).(57)  All other examples in this list of antibody modification 
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techniques result in a covalent bond between the antibody and a functional linker other than this 
protein-protein interaction category.  Engineered tags (9) include: sortase, split-proteins, coiled-
coils, spy-tag/spy-catcher, or other affinity tags in which the primary antibody is modified with 
an engineered tag that is complimentary to a secondary tag or protein that upon association or 
enzymatic reaction endows the antibody with a non-natural capability.(52,58-61)  Antibodies 
that have catalytic activity (10) are unique in that their antigen specificity is also considered their 
substrate.(62-64)  In some instances an antibody can be bi-specific in that one Fab may possess 
catalytic activity while the other has a differing antigen target or both CDR regions can have 
catalytic activity.  Antibodies with catalytic activity are rare and the de novo development of 
catalytic domains at the antibody terminus is non-trivial making this specialty category relatively 
uncommon.  
ADC FORMULATION CHALLENGES 
Unique challenges exist when formulating an ADC compared to a naked mAb.  As 
detailed earlier, sample complexity plays a major role in making formulation of a non-site 
specific ADC exceptionally difficult due to the diverse array of post conjugation species.  In 
addition, the drugs that are attached to ADCs and the linker by which the drug is attached also 
instill added complexity to formulate an ADC.(65,66)  The drugs associated with ADCs often 
have less than desirable aqueous solubility characteristics themselves.  These drugs have the 
propensity to cause inter-antibody aggregation through either exposure of protected aggregation-
prone regions within the antibody backbone upon conjugation or through drug-drug mediated 
interactions.(67-69)  This greatly limits longitudinal stability as well as high concentration 
formulation capabilities.  The drugs that are conjugated to form ADCs are also not the same from 
ADC to ADC making generalizable formulation protocols difficult to establish.(3,4) 
The means by which the drugs are attached to the antibody is also a unique hurdle that 
needs special attention when considering formulation of an ADC compared to a naked mAb.  
Linkers vary in chemical composition providing the ADC with differing cleavable capabilities.   
Cleavable linkers fall into two primary categories that allow for cleavage either through 
enzymatic digestion or exposure to pH extremes.(70-76)  There is an ever growing list of linker 
chemistries with distinctive capabilities that are being tested in diverse ADC applications.(77) 
These desirable delivery characteristics subsequently make the drug and linker susceptible to 
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premature degradation and cleavage during storage which limits the potential formulation 
compositions considerably when compared to that of formulation of a naked mAb.(75,78)  
Depending upon the selected linker and the method of conjugation of the linker to the antibody, 
critical antibody characteristics that directly affect solubility, including surface charge and zeta-
potential, can be negatively impacted.  For these reasons, drug, linker composition, and antibody 
target are all critical components specifically selected to address the unique demands of the 
intended therapeutic application and unfortunately result in significantly more complex 
formulation demands.   
CURRENT ADC FORMULATION 
As of the writing of this review there were only four FDA approved ADCs:  brentuximab 
vedotin (2012), ado-trastuzumab emtansine (2013), inotuzumab ozogamicin (2017), and 
gemtuzumab ozogamicin (2000/2017) (Table 1).(79-82)  All of these ADCs are formulated for 
IV infusion and have cancer specific indications for use.  Three of the four approved ADC 
formulations utilize non-site-specific conjugation of the cytotoxic agents to the abundant lysine 
residues found throughout the antibody surface (1).  These antibodies possess a variety of 
cleavable and non-cleavable linkers that are either susceptible to enzymatic degradation or are 
acid-labile, depending on each unique application.(83)  Brentuximab vedotin utilizes a selective 
disulfide bond reduction and subsequent thiol conjugation strategy to site-specifically conjugate 
cytotoxic auristatins to a monoclonal antibody (3).  It is not surprising that despite the high 
degree of heterogeneity associated with the non-site-specific lysine conjugation technique that it 
remains the dominant means of ADC production for clinical use due to its exceptional ease of 
use.  All of these currently approved ADC formulations are administered via intravenous 
infusion at final antibody concentrations that are < 20 mg/mL.  Thus far there has been no high 
concentration ADC formulation produced and due to the relatively low antibody concentrations 
necessary for IV infusion formulation issues that are associated with non-site-specific antibody 
conjugation techniques have been less significant.  
CONCLUSION 
Despite there being only four currently approved ADC formulations we will continue to 
see growth in the area of next-generation modified antibodies for a variety of applications as 
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there are currently >60 novel ADC formulations in clinical trials, >50% in Phase I.  While the 
demand for high concentration ADCs has been thus far limited the rapidly increasing next-gen 
antibody conjugates that are on the horizon may cause formulation to become a large issue that 
will limit routes of administration or drive more site-specific antibody modification techniques to 
be utilized.  Polyclonal antibodies and non-site-specific conjugation techniques result in very 
heterogeneous mixtures of antibodies which may make high concentration formulation more 
difficult to attain.  Site-specific conjugation should likely allow for the most optimal formulation 
and highest concentration attainable due to less conjugation variability which directly reduces 
sample complexity.  Successful high concentration antibody formulation will open the door to 
more accessible routes of administration such as intramuscular (IM) and subcutaneous (SC) 
injections which will expand the potential uses of antibodies and antibody conjugates in the 
treatment of diseases that currently remain out of reach due to the need for IV infusion.  While 
the current chemotherapeutic and cytotoxic drug conjugates will continue to rise we should see 
an increase in alternate drug conjugates for cancer and non-cancer indications such as: peptides, 
diagnostic labels, immune-mediated disorders, cardiovascular/hemostasis, neurological, 
ophthalmic, infectious disease, metabolic disorders, respiratory diseases, immunotoxins, and 
immunocytokines, to list a few.(84,85)  With the increased diversity in antibody conjugates it is 
also likely that more novel excipients, and excipient combinations, will be submitted for FDA 
clearance as the variety and complexity of next-gen antibody conjugates continues to rise. 
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FIGURE LEGENDS 
Figure 1:  Formulation difficulty increases comparing monoclonal antibodies to polyclonal 
antibodies and antibody-drug conjugates (ADCs) utilizing non-site-specific and site-specific 
conjugation strategies. 
Figure 2: (1) Natural amino acids, (2) N-terminus heavy and light chain, (3) Interchain disulfide 
bonds, (4) Carbohydrate moiety, (5) NBS photoaffinity labeling, (6) Non-natural amino acids, 
(7) Engineered cysteines, (8) Protein-protein interactions, (9) Engineered tags, (10) Catalytic
activity.
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TABLE 
Table 1: Currently FDA approved ADC formulations. 
Abbreviations: MC-VC: maleimidocaproyl-valine citrulline; MCC: maleimidomethyl 
cyclohexane1-carboxylate; AcBut: 4-(4-acetylphenoxy)butanoic acid; MMAE: monomethyl 
auristatin E; DM1:  N2′-Deacetyl-N2′-(3-mercapto1-oxopropyl)-maytansine. 
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